This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
One example is Breo Ellipta (fluticasone furoate/vilanterol), an inhalation powder approved by the Food and Drug Administration (FDA) as a once-daily maintenance treatment (not a rescue inhaler) for COPD and asthma. Most insurance companies cover some of this drug’s cost. The exact price may vary by location and pharmacy.
Currently, there is no generic version of Trulicity that’s FDA -approved. If you are on Medicare for health insurance , you might wonder: Does Medicare cover Trulicity ? The rules vary by plan, so I usually recommend checking with your insurance or having your pharmacist look it up for you,” he says.
The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. The expansion will introduce a new laboratory and advanced machinery such as a new filling line, two large size lyophilisers, a capping machine and an external vial washer.
The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) also recommended its approval in June 2025.
The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Don’t let policy changes catch you off guard.
An injectable version of lenacapavir given twice a year was approved by the US Food and Drug Administration (FDA) last month, licensed as a pre-exposure prophylaxis (PrEP) option for HIV prevention. The approval of Yeztugo was hailed as a historical breakthrough by HIV experts and charities. Sign up for our daily news round-up!
With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. As of December 2024, the company reported cash reserves of $85.2m. Give your business an edge with our leading industry insights.
Find out more After its strategic review, the company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability. This approach should maintain access to a $600m revolving credit facility while managing liabilities proactively, including repayment of convertible notes due in 2027.
Without insurance, the cost of Stiolto Respimat can be over $600 per month. For many people, the retail price of Stiolto Respimat can make getting treatment difficult without insurance coverage. Currently, there is no generic version of Stiolto Respimat approved by the Food and Drug Administration (FDA). mcg tiotropium and 2.5
Is Eucrisa covered by insurance? | How much does Eucrisa cost without insurance? | How to get Eucrisa without insurance. Eucrisa is a FDA-approved nonsteroidal prescription drug. The soonest date a generic may come on the market is between 2027 and 2030, but this is not certain. Is Eucrisa covered by insurance?
While Lumigan is a 0.01% solution of bimatoprost and no generic product is manufactured at this concentration, patents on Lumigan expire in 2025 and 2027, so there may be a generic option approved by the Food and Drug Administration (FDA) thereafter. Is Lumigan covered by insurance? How much does Lumigan cost without insurance?
Is Nexplanon covered by insurance? | How much does Nexplanon cost without insurance? | How to get Nexplanon without insurance Nexplanon is a brand-name prescription birth control implant that does not contain estrogen. in 2027 and other countries in 2025, when a generic version may be approved.
Is Spiriva Respimat covered by insurance? | How much does Spiriva Respimat cost without insurance? | How to get Spiriva Respimat without insurance. Spiriva Respimat is also FDA-approved as a long-term maintenance treatment for asthma in adults and children six years or older. Is Spiriva Respimat covered by insurance?
A qualifying medication is prescribed by their healthcare provider The patients who have no insurance or have Medicare Part D Patients who are not enrolled in Medicaid, full Low-Income Subsidy, or Veterans (VA) benefits. The patient must-have commercial health insurance to use the savings card. Virgin Islands.
In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. The drug was approved to treat type 2 diabetes mellitus in May. Access to anti-obesity medications.
In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. The drug was approved to treat type 2 diabetes mellitus in May. Access to anti-obesity medications.
The FDA first approved vortioxetine to treat major depressive disorder in 2013. That might differ slightly in the US, but even when the Trintellix patent ends in 2026, its generic probably wont debut until 2027 or later. Until then, there are other ways to save on Trintellix , whether or not you have insurance coverage.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content